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Fact Sheet for Healthcare Providers: Interpreting Trioplex Real-Time RT-
PCR Assay (Trioplex rRT-PCR) Results 
 
Updated: March 1, 2017 
Dear Healthcare Provider: 
 
The US Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) 
to authorize the use of the Centers for Disease Control and Prevention (CDC) Trioplex Real-time 
RT-PCR Assay (Trioplex rRT-PCR) for the in vitro qualitative detection of Zika virus with specified 
instruments.  This assay tests for Zika virus, dengue virus and chikungunya virus RNA in serum, as 
well as whole blood and cerebrospinal fluid (CSF) (each collected alongside a patient-matched 
serum specimen).  The assay also tests for Zika virus in urine, and amniotic fluid specimens (each 
collected alongside a patient-matched serum specimen). Testing should be conducted on 
specimens from people who meet CDC Zika clinical and/or epidemiologic criteria for testing and be 
performed in laboratories designated by the CDC; see www.cdc.gov/zika/hc-providers/index.html. 
This test is should be performed according to CDC’s algorithm for Zika testing (see 
http://www.cdc.gov/zika/laboratories/lab-guidance.html). 
 
The information in this Fact Sheet is to inform you of the significant known and potential risks and 
benefits of the emergency use of the Trioplex rRT-PCR (see 
www.fda.gov/MedicalDevices/Safety/EmergencySituations/ucm161496.htm). 
  
Why is this test needed at this time? 
Public health officials have determined that Zika virus poses a potential public health emergency.  
Current information on Zika virus infection for healthcare providers, including case definitions and 
information about signs and symptoms, is available at www.cdc.gov/zika/hc-providers/index.html. 
All information and guidance, including those on Zika virus laboratory testing, may change as more 
data are gathered on this virus.  Please check CDC’s Zika virus website regularly for the most 
current information (www.cdc.gov/zika/index.html). 
 
The US Secretary of Health and Human Services (HHS) has declared that circumstances exist to 
justify the emergency use of in vitro diagnostic tests for the detection of Zika virus and/or diagnosis 
of Zika virus infection. This EUA will terminate when the HHS Secretary’s declaration terminates, 
unless FDA revokes it sooner. 
 
At this time, there are no FDA approved/cleared tests available that can detect Zika virus in clinical 
specimens in the United States.  Therefore, CDC has developed the Trioplex rRT-PCR test to 
detect evidence of Zika virus infection and aid in differentiating this infection from dengue and 
chikungunya virus infections.  
 
When should the Trioplex rRT-PCR test be performed?   
If Zika virus infection is suspected based on CDC’s published clinical and/or epidemiologic criteria, 
the Trioplex rRT-PCR may be ordered and should be performed according to the CDC-issued 
guidance (http://www.cdc.gov/zika/laboratories/lab-guidance.html).  The algorithms included within 
the guidance illustrate the appropriate Zika testing approach based on the presence of signs and 
symptoms, pregnancy status, and the time between onset of symptoms or suspected exposure 
and specimen collection. Please contact your state or local health department to facilitate testing.   
 
As disease manifestations of dengue and chikungunya virus infections can resemble those of Zika 
virus infection, this assay may be useful in differentiating dengue and chikungunya virus infections 
from Zika virus infections or identifying possible co-infections.   
 
Zika, dengue, and chikungunya virus RNA is typically detectable in serum during the acute phase 
of infection (generally up to 7 days post-symptom onset). Zika virus RNA has been detected in 
serum up to 13 days post-symptom onset in non-pregnant patients, and up to 62 days post-
symptom onset in pregnant patients.  In addition, Zika virus RNA has been detected up to 53 days 
after the last known possible exposure in an asymptomatic pregnant woman (references 3-4).   
 
As of March 1, 2017 serum is the primary diagnostic specimen for Zika virus, dengue virus, and 
chikungunya virus RNA and serologic testing, and should be the priority specimen for collection 
and Trioplex rRT-PCR testing. Trioplex rRT-PCR can also be used to test whole blood, 
cerebrospinal fluid (CSF), urine, and amniotic fluid specimens (each collected alongside a patient-
matched serum).  While some data from the United States suggests that Zika virus RNA may be 
detectible for longer periods of time in urine and whole blood than in serum, persistence of Zika 
virus RNA in urine, whole blood, CSF, and amniotic fluid is not well characterized.  CSF and 
amniotic fluid are not recommended for routine diagnosis of Zika virus infection.  Note: CDC 
updated this fact sheet in September 2016 to add whole blood as a specimen type. 
 
Along with serum specimens, healthcare providers are strongly encouraged to collect and submit 
additional recommended specimens (per CDC guidance), such as urine and whole blood, to 
provide additional opportunities for detection of Zika virus infection.  However, a patient-matched 
serum specimen should always be submitted with any other type of fluid specimen.   
 
Specimens should be collected with appropriate infection control precautions and according to the 
manufacturer’s instructions for the specimen collection device, handling, and storage.  Serum 
should be collected in serum separator tubes and centrifuged after collection to reduce the 
likelihood of hemolysis. Whole blood should be collected in EDTA tubes.  Additional guidance for 
collection of body fluid specimens for Zika diagnostic testing may be found at: 
http://www.cdc.gov/zika/laboratories/test-specimens-bodyfluids.html. 
 
If your patient has been symptomatic but is beyond the recommended window for Trioplex testing, 
serologic testing for antibodies to Zika virus may be helpful. 
 
What does it mean if the specimen tests positive for Zika virus RNA?  
 
A positive test result for Zika virus from the Trioplex rRT-PCR indicates that RNA from Zika virus 
was detected in the patient’s specimen. A positive test result in any specimen collected from a 
patient is indicative of Zika virus infection.  Laboratory test results should always be considered in 
the context of clinical observations, epidemiologic data, and travel history in making a final 
diagnosis and patient management decisions.  For guidance on Zika virus, please refer to 
www.cdc.gov/zika/hc-providers/index.html. 
 
The Trioplex rRT-PCR has been designed to minimize the likelihood of false positive test 
results.  Cross-reactivity of any of the components of this test resulting in false positive results is 
not expected.  However, in the event of a false positive result, risks to patients could include any or 
all of the following:  impaired ability to detect and receive appropriate medical care for the true 
source of symptoms; in the case of pregnant women, an unnecessary increase in the monitoring of 
a woman’s pregnancy; other unintended adverse effects.  
 
In the United States and its territories, Zika virus infection and disease (non-congenital and 
congenital) are nationally notifiable conditions and should be reported to the local or state health 
department. For guidance on Zika virus, please refer to http://www.cdc.gov/zika/hc-
providers/index.html. 
 
While there is an established association between Zika virus infection during pregnancy and 
microcephaly, detection of Zika virus RNA in specimens collected from a pregnant woman does 
not provide definitive information about the health of her fetus and does not indicate imminent harm 
to her fetus.  If a pregnant woman is diagnosed with Zika virus infection based on detection of Zika 
virus RNA, issues such as timing of infection during the course of pregnancy, presence of 
symptoms and other factors may help determine the risk to her fetus.   
 
What does it mean if the specimen tests positive for dengue or chikungunya virus RNA? 
 
A positive test result for dengue or chikungunya viruses from the Trioplex rRT-PCR indicates that 
RNA from dengue and/or chikungunya was detected in the patient’s specimen. Laboratory test 
results should always be considered in the context of clinical observations, epidemiologic data, and 
travel history in making a final diagnosis and patient management decisions.   
 
The Trioplex rRT-PCR assay has been designed to minimize the likelihood of false positive test 
results.  Cross reactivity of any of the components of this test that may lead to false positive results 
is not expected.  However, in the event of a false-positive result, risks to patients could include 
impaired ability to detect and receive appropriate medical care for the true source of symptoms, or 
other unintended adverse effects. Any positive test result for dengue or chikungunya virus should 
be reported to your local and state health department.  
 
While co-infections are rare, using the Trioplex rRT-PCR, it is possible to detect more than one of 
these three viruses in a patient.  
 
In the United States and its territories, dengue and chikungunya virus infections are nationally 
notifiable diseases. Information for clinicians caring for patients with dengue or chikungunya virus 
infection is available on CDC’s websites: 
 
Dengue clinical guidance: www.cdc.gov/dengue/clinicallab/index.html 
 
Chikungunya clinical guidance: www.cdc.gov/chikungunya/hc/index.html 
 
What does it mean if the specimen tests negative for Zika virus RNA (or dengue virus RNA 
or chikungunya virus RNA)?  
 
A negative test result for Zika, dengue, and/or chikungunya viruses in the specimen means that 
RNA from Zika, dengue, and/or chikungunya viruses is not present in the specimen above the 
test’s limit of detection. However, a negative result for one or more of these arboviruses does not 
rule out infection with the virus(es) and should not be used as the sole basis for treatment or other 
patient management decisions.   
 
It is especially important to note that negative results in urine, whole blood, CSF, and amniotic fluid 
which are not the recommended primary diagnostic specimen types, do not necessarily mean that 
a person is not infected.  When results are negative for these specimen types, the patient-matched 
serum specimen should be tested as outlined in the current CDC-issued algorithm 
(http://www.cdc.gov/zika/laboratories/lab-guidance.html).   
 
A negative Trioplex rRT-PCR Zika virus test result does not exclude the possibility of Zika virus 
infection.  In serum, negative rRT-PCR test results are known to occur in Zika virus infection, 
particularly if testing is conducted outside the acute phase of infection (generally up to 7 days post 
symptom-onset) or in asymptomatic people.  When other diagnostic testing is negative, the 
possibility of a false negative result should be considered in the context of a patient’s recent 
exposures and the presence of clinical signs and symptoms consistent with Zika virus infection.  
Such patients should have antibody testing performed on their serum sample, as per the CDC 
testing algorithm (found at http://www.cdc.gov/zika/laboratories/lab-guidance.html). 
   
Absence of laboratory evidence of Zika virus infection cannot definitively rule out Zika virus 
infection in persons with epidemiologic risk factors.  All results should be considered in the context 
of clinical signs and symptoms, exposure risk and time since symptom onset, or in the absence of 
symptoms, time since exposure. 
 
Guidance for healthcare providers, including those caring for pregnant women and women of 
reproductive age with possible Zika virus exposure, is available on the CDC website: 
www.cdc.gov/zika/hc-providers/index.html. 
 
What has changed in this update to the Fact Sheet for Healthcare Providers? 
 
The main changes that have been made to the Fact Sheet for Healthcare Providers are the 
following: 
• Whole blood has been added as an acceptable specimen type, when collected alongside a 
patient-matched serum specimen. 
• Indications for testing and guidance for interpretation of a negative result have been 
updated to align with recently posted CDC Guidance for US Laboratories Testing for Zika 
Virus Infection (http://www.cdc.gov/zika/laboratories/lab-guidance.html). 
 
Reporting Adverse Events  
 
You should report adverse events, including problems with test performance or results, to 
MedWatch at http://www.fda.gov/Safety/MedWatch/default.htm, by completing and submitting the 
online FDA Form 3500 for Health Professionals (available at 
https://www.accessdata.fda.gov/scripts/medwatch/index.cfm?action=reporting.home) or by calling 
1-800-FDA-1088.  
All patients should receive the Fact Sheet for Patients: Understanding Results from the 
Trioplex Real-Time RT-PCR Assay (Trioplex rRT-PCR). 
 
Contact Information for the Manufacturer: 
CDC Emergency Operations Center (EOC) 
1600 Clifton Road 
Atlanta, Georgia, USA, 30329 
Office phone: CDC EOC (770-488-7100)  
 
Any significant new findings that negatively impact the performance of the test and that are 
observed during the course of the emergency use of the Trioplex rRT-PCR Assay will be made 
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